{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:33:10Z","timestamp":1788838390474,"version":"build-2803163510"},"reference-count":118,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2023R1A2C3003864 and RS-2023-00213119"],"award-info":[{"award-number":["NRF-2023R1A2C3003864 and RS-2023-00213119"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2023-00217266"],"award-info":[{"award-number":["RS-2023-00217266"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI21C1218"],"award-info":[{"award-number":["HI21C1218"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecules and Cells"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.14348\/molcells.2023.0079","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T01:09:46Z","timestamp":1697677786000},"page":"579-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8758-9628","authenticated-orcid":false,"given":"Sehan","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2637-9436","authenticated-orcid":false,"given":"Sharmin","family":"Afroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1966-1397","authenticated-orcid":false,"given":"Donghyun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-6014","authenticated-orcid":false,"given":"Jeonghwan","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-863X","authenticated-orcid":false,"given":"Jooyeon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-5342","authenticated-orcid":false,"given":"June Hyuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-5171","authenticated-orcid":false,"given":"Hye Jin","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1994-6990","authenticated-orcid":false,"given":"Hyun Guy","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1763-4267","authenticated-orcid":false,"given":"Yi-Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6480-1929","authenticated-orcid":false,"given":"Jin-Hong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14348\/molcells.2023.0079_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.14348\/molcells.2023.0079_bib2","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol. Ther."},{"key":"10.14348\/molcells.2023.0079_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","article-title":"Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors","volume":"46","author":"Arce Vargas","year":"2017","journal-title":"Immunity"},{"issue":"Suppl 1","key":"10.14348\/molcells.2023.0079_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3747\/co.27.5407","article-title":"Immunotherapy in soft-tissue sarcoma","volume":"27","author":"Ayodele","year":"2020","journal-title":"Curr. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Balachandran","year":"2011","journal-title":"Nat. Med."},{"key":"10.14348\/molcells.2023.0079_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.14348\/molcells.2023.0079_bib8","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3390\/cancers14112694","article-title":"Surgical treatment of bone sarcoma","volume":"14","author":"Blasius","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.14348\/molcells.2023.0079_bib9","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","year":"2017","journal-title":"Cell"},{"key":"10.14348\/molcells.2023.0079_bib10","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1002\/ijc.32743","article-title":"GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma","volume":"146","author":"Charan","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.14348\/molcells.2023.0079_bib11","doi-asserted-by":"crossref","first-page":"e79655","DOI":"10.7554\/eLife.79655","article-title":"Non-coding RNAs in drug and radiation resistance of bone and soft-tissue sarcoma: a systematic review","volume":"11","author":"Chen","year":"2022","journal-title":"Elife"},{"issue":"16 Suppl","key":"10.14348\/molcells.2023.0079_bib12","doi-asserted-by":"crossref","first-page":"11562","DOI":"10.1200\/JCO.2022.40.16_suppl.11562","article-title":"Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (\u201cAfami-cel\u201d [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid\/round cell liposarcoma phase 1 and phase 2 trials","volume":"40","author":"D\u2019Angelo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.14348\/molcells.2023.0079_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","article-title":"Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment","volume":"46","author":"D\u2019Angelo","year":"2015","journal-title":"Hum. Pathol."},{"key":"10.14348\/molcells.2023.0079_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13569-019-0119-0","article-title":"Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes","volume":"9","author":"de Jong","year":"2019","journal-title":"Clin. Sarcoma Res."},{"key":"10.14348\/molcells.2023.0079_bib16","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-20-4513","article-title":"First-in-human phase I study of ABBV-085, an antibody-drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors","volume":"27","author":"Demetri","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.14348\/molcells.2023.0079_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.042","article-title":"Tumor-derived retinoic acid regulates intratumoral monocyte differentiation to promote immune suppression","volume":"180","author":"Devalaraja","year":"2020","journal-title":"Cell"},{"key":"10.14348\/molcells.2023.0079_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.14348\/molcells.2023.0079_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pathol.2021.11.008","article-title":"Tumour mutational burden: an overview for pathologists","volume":"54","author":"Doig","year":"2022","journal-title":"Pathology"},{"key":"10.14348\/molcells.2023.0079_bib20","doi-asserted-by":"crossref","first-page":"564852","DOI":"10.3389\/fonc.2020.564852","article-title":"Heterogeneity of soft tissue sarcomas and its implications in targeted therapy","volume":"10","author":"Du","year":"2020","journal-title":"Front. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41416-020-01160-5","article-title":"Emerging immunotherapies for metastasis","volume":"124","author":"Edwards","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.14348\/molcells.2023.0079_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"10.14348\/molcells.2023.0079_bib23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2217\/imt.12.3","article-title":"Cellular immunotherapy for soft tissue sarcomas","volume":"4","author":"Finkelstein","year":"2012","journal-title":"Immunotherapy"},{"key":"10.14348\/molcells.2023.0079_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma","volume":"13","author":"Gelderblom","year":"2008","journal-title":"Oncologist"},{"key":"10.14348\/molcells.2023.0079_bib25","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.14348\/molcells.2023.0079_bib26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.1984.2.5.425","article-title":"Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients","volume":"2","author":"Goorin","year":"1984","journal-title":"J. Clin. Oncol."},{"issue":"21s","key":"10.14348\/molcells.2023.0079_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2217\/fon-2021-0449","article-title":"Surgery in soft tissue sarcoma: the thin line between a surgical or more conservative approach","volume":"17","author":"Gronchi","year":"2021","journal-title":"Future Oncol."},{"key":"10.14348\/molcells.2023.0079_bib28","doi-asserted-by":"crossref","first-page":"e11131","DOI":"10.15252\/emmm.201911131","article-title":"Sarcoma treatment in the era of molecular medicine","volume":"12","author":"Grunewald","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.14348\/molcells.2023.0079_bib29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.14348\/molcells.2023.0079_bib30","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.4081\/ejh.2022.3377","article-title":"Clinicopathological assessment of cancer\/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma","volume":"66","author":"Hashimoto","year":"2022","journal-title":"Eur. J. Histochem."},{"key":"10.14348\/molcells.2023.0079_bib31","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/modpathol.2013.244","article-title":"Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma","volume":"27","author":"Hemminger","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.14348\/molcells.2023.0079_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.14348\/molcells.2023.0079_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13014-016-0668-9","article-title":"Soft tissue sarcoma of the extremities: pending questions on surgery and radiotherapy","volume":"11","author":"Hoefkens","year":"2016","journal-title":"Radiat. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib34","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.14348\/molcells.2023.0079_bib35","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.7150\/thno.73714","article-title":"Single-cell transcriptomics reveals the regulative roles of cancer associated fibroblasts in tumor immune microenvironment of recurrent osteosarcoma","volume":"12","author":"Huang","year":"2022","journal-title":"Theranostics"},{"key":"10.14348\/molcells.2023.0079_bib36","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.suc.2016.05.005","article-title":"Epidemiology and etiology of sarcomas","volume":"96","author":"Hui","year":"2016","journal-title":"Surg. Clin. North Am."},{"key":"10.14348\/molcells.2023.0079_bib37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12885-023-10758-w","article-title":"Clinical markers of immunotherapy outcomes in advanced sarcoma","volume":"23","author":"Husain","year":"2023","journal-title":"BMC Cancer"},{"key":"10.14348\/molcells.2023.0079_bib38","doi-asserted-by":"crossref","first-page":"e29442","DOI":"10.1002\/pbc.29442","article-title":"Current approaches to management of bone sarcoma in adolescent and young adult patients","volume":"69","author":"Ingley","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"10.14348\/molcells.2023.0079_bib39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00428-017-2206-z","article-title":"MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1","volume":"471","author":"Iura","year":"2017","journal-title":"Virchows Arch."},{"key":"10.14348\/molcells.2023.0079_bib40","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.14348\/molcells.2023.0079_bib41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ijc.1451","article-title":"Monophasic and biphasic synovial sarcomas abundantly express cancer\/testis antigen NY-ESO-1 but not MAGE-A1 or CT7","volume":"94","author":"Jungbluth","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.14348\/molcells.2023.0079_bib42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(03)00982-3","article-title":"Cancer\/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies","volume":"4","author":"Juretic","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.14348\/molcells.2023.0079_bib43","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/bjc.2012.57","article-title":"The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting","volume":"106","author":"Kailayangiri","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.14348\/molcells.2023.0079_bib44","first-page":"3937","article-title":"Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma","volume":"17","author":"Kakimoto","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.14348\/molcells.2023.0079_bib45","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/j.1349-7006.2012.02370.x","article-title":"SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group","volume":"103","author":"Kawaguchi","year":"2012","journal-title":"Cancer Sci."},{"key":"10.14348\/molcells.2023.0079_bib46","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial","volume":"6","author":"Kelly","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.14348\/molcells.2023.0079_bib47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s12885-016-2451-6","article-title":"Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Cancer"},{"key":"10.14348\/molcells.2023.0079_bib48","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1038\/s41467-020-18817-7","article-title":"A system-level approach identifies HIF-2alpha as a critical regulator of chondrosarcoma progression","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.14348\/molcells.2023.0079_bib49","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jso.26306","article-title":"The emerging role of immunotherapy for the treatment of sarcoma","volume":"123","author":"Klemen","year":"2021","journal-title":"J. Surg. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib50","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","article-title":"LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity","volume":"611","author":"Krishnamurty","year":"2022","journal-title":"Nature"},{"key":"10.14348\/molcells.2023.0079_bib51","first-page":"1","article-title":"Beyond tumor PD-L1: emerging genomic biomarkers for checkpoint inhibitor immunotherapy","volume":"40","author":"Lagos","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.14348\/molcells.2023.0079_bib52","doi-asserted-by":"crossref","first-page":"784","DOI":"10.14348\/molcells.2021.0130","article-title":"TJP1 contributes to tumor progression through supporting cell-cell aggregation and communicating with tumor microenvironment in leiomyosarcoma","volume":"44","author":"Lee","year":"2021","journal-title":"Mol. Cells"},{"key":"10.14348\/molcells.2023.0079_bib53","doi-asserted-by":"crossref","first-page":"363","DOI":"10.14348\/molcells.2021.0044","article-title":"Clinical perspectives to overcome acquired resistance to anti-programmed death-1 and anti-programmed death ligand-1 therapy in non-small cell lung cancer","volume":"44","author":"Lee","year":"2021","journal-title":"Mol. Cells"},{"key":"10.14348\/molcells.2023.0079_bib54","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41420-022-01107-0","article-title":"Mesenchymal\/stromal stem cells: necessary factors in tumour progression","volume":"8","author":"Li","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.14348\/molcells.2023.0079_bib55","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1007\/s13277-014-1634-5","article-title":"Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2\/M checkpoint response and apoptosis in osteosarcoma cells","volume":"35","author":"Li","year":"2014","journal-title":"Tumour Biol."},{"key":"10.14348\/molcells.2023.0079_bib56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-019-0770-1","article-title":"Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib57","doi-asserted-by":"crossref","first-page":"107475","DOI":"10.1016\/j.ijscr.2022.107475","article-title":"Case series of high-grade soft tissue sarcoma of the lower limb with delayed diagnosis: experience at a tertiary hospital in northern Tanzania","volume":"97","author":"Lodhia","year":"2022","journal-title":"Int. J. Surg. Case Rep."},{"key":"10.14348\/molcells.2023.0079_bib58","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.14348\/molcells.2023.0079_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"key":"10.14348\/molcells.2023.0079_bib60","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3390\/cancers12071962","article-title":"Non-conventional treatments for conventional chondrosarcoma","volume":"12","author":"Monga","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.14348\/molcells.2023.0079_bib61","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fimmu.2020.00274","article-title":"IDO targeting in sarcoma: biological and clinical implications","volume":"11","author":"Nafia","year":"2020","journal-title":"Front. Immunol."},{"key":"10.14348\/molcells.2023.0079_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"13 Suppl","key":"10.14348\/molcells.2023.0079_bib63","article-title":"Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas","volume":"79","author":"Navai","year":"2019","journal-title":"Cancer Res."},{"key":"10.14348\/molcells.2023.0079_bib64","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1172\/JCI28045","article-title":"In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines","volume":"116","author":"Nishikawa","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.14348\/molcells.2023.0079_bib65","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib66","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"},{"key":"10.14348\/molcells.2023.0079_bib67","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.critrevonc.2015.01.004","article-title":"Treating metastatic sarcomas locally: a paradoxe, a rationale, an evidence?","volume":"95","author":"Olivier","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.14348\/molcells.2023.0079_bib68","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.7150\/thno.72800","article-title":"Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness","volume":"12","author":"Panagi","year":"2022","journal-title":"Theranostics"},{"key":"10.14348\/molcells.2023.0079_bib69","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1245\/s10434-016-5755-5","article-title":"Surveillance imaging patterns and outcomes following radiation therapy and radical resection for localized extremity and trunk soft tissue sarcoma","volume":"24","author":"Patel","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib70","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1245\/ASO.2006.05.035","article-title":"Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma","volume":"13","author":"Pawlik","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12032-016-0807-z","article-title":"Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas","volume":"33","author":"Paydas","year":"2016","journal-title":"Med. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib72","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.14348\/molcells.2023.0079_bib73","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","article-title":"LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates","volume":"78","author":"Purcell","year":"2018","journal-title":"Cancer Res."},{"key":"10.14348\/molcells.2023.0079_bib74","doi-asserted-by":"crossref","first-page":"9536","DOI":"10.1021\/acsnano.7b05465","article-title":"Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages","volume":"11","author":"Qian","year":"2017","journal-title":"ACS Nano"},{"key":"10.14348\/molcells.2023.0079_bib75","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccr.2011.01.020","article-title":"Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth","volume":"19","author":"Quante","year":"2011","journal-title":"Cancer Cell"},{"key":"10.14348\/molcells.2023.0079_bib76","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11864-009-0088-2","article-title":"The clinical management of chondrosarcoma","volume":"10","author":"Riedel","year":"2009","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.14348\/molcells.2023.0079_bib77","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.14348\/molcells.2023.0079_bib78","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.28461","article-title":"Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma","volume":"120","author":"Roth","year":"2014","journal-title":"Cancer"},{"key":"10.14348\/molcells.2023.0079_bib79","first-page":"25","article-title":"Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance","volume":"5","author":"Rytlewski","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"10.14348\/molcells.2023.0079_bib80","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.21037\/atm-20-6041","article-title":"Turning \u2019Cold\u2019 tumors \u2019Hot\u2019: immunotherapies in sarcoma","volume":"9","author":"Rytlewski","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.14348\/molcells.2023.0079_bib81","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13000-022-01251-2","article-title":"Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1\/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors","volume":"17","author":"Samiei","year":"2022","journal-title":"Diagn. Pathol."},{"key":"10.14348\/molcells.2023.0079_bib82","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/0008-5472.CAN-17-0032","article-title":"Epithelial-to-mesenchymal and mesenchymal-to-epithelial transition in mesenchymal tumors: a paradox in sarcomas?","volume":"77","author":"Sannino","year":"2017","journal-title":"Cancer Res."},{"key":"10.14348\/molcells.2023.0079_bib83","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.4049\/jimmunol.169.3.1611","article-title":"Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma","volume":"169","author":"Sato","year":"2002","journal-title":"J. Immunol."},{"key":"10.14348\/molcells.2023.0079_bib84","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.14348\/molcells.2023.0079_bib85","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.14348\/molcells.2023.0079_bib86","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41416-021-01456-0","article-title":"T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study","volume":"125","author":"Smolle","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.14348\/molcells.2023.0079_bib87","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.14348\/molcells.2023.0079_bib88","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jss.2019.08.002","article-title":"Trends in the use of adjuvant chemotherapy for high-grade truncal and extremity soft tissue sarcomas","volume":"245","author":"Squires","year":"2020","journal-title":"J. Surg. Res."},{"key":"10.14348\/molcells.2023.0079_bib89","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.14348\/molcells.2023.0079_bib90","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.4161\/21645515.2014.973317","article-title":"Antigen-specific vaccines for cancer treatment","volume":"10","author":"Tagliamonte","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.14348\/molcells.2023.0079_bib91","doi-asserted-by":"crossref","first-page":"109821","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.14348\/molcells.2023.0079_bib92","doi-asserted-by":"crossref","first-page":"188606","DOI":"10.1016\/j.bbcan.2021.188606","article-title":"Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials","volume":"1876","author":"Tang","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.14348\/molcells.2023.0079_bib93","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.14348\/molcells.2023.0079_bib94","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/jso.26308","article-title":"Chondrosarcoma local recurrence in the Cancer Registry of Norway cohort (1990-2013): patterns and impact","volume":"123","author":"Thorkildsen","year":"2021","journal-title":"J. Surg. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib95","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00262-019-02322-y","article-title":"An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma","volume":"68","author":"Tsagozis","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.14348\/molcells.2023.0079_bib96","doi-asserted-by":"crossref","first-page":"48296","DOI":"10.18632\/oncotarget.10219","article-title":"Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3","volume":"7","author":"Tu","year":"2016","journal-title":"Oncotarget"},{"key":"10.14348\/molcells.2023.0079_bib97","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nri3902","article-title":"Immunological hallmarks of stromal cells in the tumour microenvironment","volume":"15","author":"Turley","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.14348\/molcells.2023.0079_bib98","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.1245\/s10434-021-09942-8","article-title":"Late local recurrence and metastasis in soft tissue sarcoma of the extremities and trunk wall: better outcome after treatment of late events compared with early","volume":"28","author":"von Konow","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib99","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.14348\/molcells.2023.0079_bib100","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events","volume":"12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"key":"10.14348\/molcells.2023.0079_bib101","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2019.10.024","article-title":"Cancer testis antigens in sarcoma: expression, function and immunotherapeutic application","volume":"479","author":"Wei","year":"2020","journal-title":"Cancer Lett."},{"key":"10.14348\/molcells.2023.0079_bib102","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12865-022-00522-3","article-title":"The immune subtypes and landscape of sarcomas","volume":"23","author":"Weng","year":"2022","journal-title":"BMC Immunol."},{"key":"10.14348\/molcells.2023.0079_bib103","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev-pharmtox-011112-140326","article-title":"Cause and consequence of cancer\/testis antigen activation in cancer","volume":"54","author":"Whitehurst","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.14348\/molcells.2023.0079_bib104","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1302\/0301-620X.97B5.35131","article-title":"Can local recurrence of a sacral chordoma be treated by further surgery?","volume":"97-B","author":"Xie","year":"2015","journal-title":"Bone Joint J."},{"key":"10.14348\/molcells.2023.0079_bib105","doi-asserted-by":"crossref","first-page":"595527","DOI":"10.3389\/fonc.2020.595527","article-title":"The clinical implications of tumor mutational burden in osteosarcoma","volume":"10","author":"Xie","year":"2021","journal-title":"Front. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib106","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.14348\/molcells.2023.0079_bib107","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","article-title":"Immunogenic neoantigens derived from gene fusions stimulate T cell responses","volume":"25","author":"Yang","year":"2019","journal-title":"Nat. Med."},{"key":"10.14348\/molcells.2023.0079_bib108","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1158\/1078-0432.CCR-20-0328","article-title":"Mogamulizumab in combination with durvalumab or tremelimumab in patients with advanced solid tumors: a phase I study","volume":"26","author":"Zamarin","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.14348\/molcells.2023.0079_bib109","doi-asserted-by":"crossref","first-page":"736146","DOI":"10.3389\/fsurg.2021.736146","article-title":"Clinical significance and risk factors of local recurrence in synovial sarcoma: a retrospective analysis of 171 cases","volume":"8","author":"Zhang","year":"2022","journal-title":"Front. Surg."},{"key":"10.14348\/molcells.2023.0079_bib110","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.14348\/molcells.2023.0079_bib111","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Immunol."},{"key":"10.14348\/molcells.2023.0079_bib112","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1111\/ajco.12807","article-title":"Local recurrence is correlated with decreased overall survival in patients with intermediate high-grade localized primary soft tissue sarcoma of extremity and abdominothoracic wall","volume":"14","author":"Zhao","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.14348\/molcells.2023.0079_bib113","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/apm.12311","article-title":"Expression of programmed death 1 is correlated with progression of osteosarcoma","volume":"123","author":"Zheng","year":"2015","journal-title":"APMIS"},{"key":"10.14348\/molcells.2023.0079_bib114","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13287-018-0780-x","article-title":"Mesenchymal stem cells in the osteosarcoma microenvironment: their biological properties, influence on tumor growth, and therapeutic implications","volume":"9","author":"Zheng","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.14348\/molcells.2023.0079_bib115","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","article-title":"Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.14348\/molcells.2023.0079_bib116","doi-asserted-by":"crossref","first-page":"102115","DOI":"10.1016\/j.ctrv.2020.102115","article-title":"Sarcomas: immune biomarker expression and checkpoint inhibitor trials","volume":"91","author":"Zhu","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.14348\/molcells.2023.0079_bib117","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri1936","article-title":"Cancer despite immunosurveillance: immunoselection and immunosubversion","volume":"6","author":"Zitvogel","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.14348\/molcells.2023.0079_bib118","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/cncr.26486","article-title":"Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis","volume":"118","author":"Zou","year":"2012","journal-title":"Cancer"}],"container-title":["Molecules and Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pdf.medrang.co.kr\/KSMCB\/2023\/046\/KSMCB046-10-02.pdf","content-type":"unspecified","content-version":"tdm","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1016847823252589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1016847823252589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pdf.medrang.co.kr\/KSMCB\/2023\/046\/KSMCB046-10-02.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T17:56:21Z","timestamp":1760896581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1016847823252589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":118,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1016847823252589"],"URL":"https:\/\/doi.org\/10.14348\/molcells.2023.0079","relation":{},"ISSN":["1016-8478"],"issn-type":[{"value":"1016-8478","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities","name":"articletitle","label":"Article Title"},{"value":"Molecules and Cells","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14348\/molcells.2023.0079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 THE AUTHORS. Published by Elsevier Inc on behalf of the Korean Society for Molecular and Cellular Biology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}